Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.57 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | ME2 | P23368 | 1/20 | 0.54 |
| ▸ | ME1 | P48163 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860430 | 0.84 | MEN1 (0.58) | MEN1KMT2AALDH1A1CACNA2D1CACNA1B | |
| SCHEMBL3862189 | 0.83 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL6893687 | 0.83 | ALDH1A1 (0.79) | MEN1KMT2AALDH1A1NPC1KDM4E | |
| SCHEMBL26330969 | 0.81 | CACNA2D1 (0.81) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL5027731 | 0.79 | CACNA2D1 (0.57) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL5308137 | 0.79 | MEN1 (0.60) | MEN1KMT2AALDH1A1NPC1KDM4E | |
| SCHEMBL14192211 | 0.78 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1NPC1KDM4E | |
| SCHEMBL5314683 | 0.78 | MEN1 (0.62) | MEN1KMT2AALDH1A1NPC1KDM4E | |
| SCHEMBL31520485 | 0.78 | MEN1 (1.00) | MEN1KMT2AALDH1A1NPC1KDM4E | |
| SCHEMBL5308328 | 0.78 | HDAC3 (0.61) | MEN1KMT2AALDH1A1NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | MEN1 2981/4885KMT2A 3192/4885ALDH1A1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.